The safety profile of drotrecogin alfa (activated)
Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safety analyses since 1995. However, the only comprehensive review of all trials is that reporte...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230610/ |